Quick Listen: Scrip’s Five Must-Know Things - Clone

 
• By Saba Afreen
  
Generate a summary of this article
Listen to this article
Beta

desciption description

Subscribe: Apple Podcasts, SoundCloud, TuneIn and Spotify Podcasts,

Join us for an audio catch-up on the major events in the global biopharma industry over the past business week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended October 3, 2025 including: Pfizer’s backroom US pricing deal; confusion over Japan’s pharma tariffs; more direct-to-patient schemes in the US; first approval for Novartis’s remibrutinib; and GSK’s CEO to step down.

For additional disclaimers and regulatory disclosures, please visit

https://insights.citeline.com/scrip/podcasts/

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Scrip

Sponsored by :

Clinical Trial Complexity Is Reshaping Evidence Collection Clinical trial innovation has historical - Clone

As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.

Easy Access To GLP-1s Is Causing Big Problems For Obesity Studies

in the expanding and competitive field of obesity therapy clinical trials, one trend is increasingly causing a headache: placebo-arm participants dropping out or using “off-protocol” weight-loss treatments while on trial.

Test

Sponsored by :

Clinical Trial Complexity Is Reshaping Evidence Collection Clinical trial innovation has historical

As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.

More from